Ivermectin fails to curb hospitalizations, 2nd large study shows

Ivermectin, an anti-parasitic drug used as an alternative treatment for COVID-19, did not reduce hospital admissions, a study published March 30 in The New England Journal of Medicine found. 

Advertisement

It is the second recent study to show ivermectin didn’t improve patient outcomes for factors related to COVID-19 infection. Researchers analyzed 3,515 symptomatic COVID-19 positive adults recruited from 12 public health clinics across Brazil between March 23, 2021, and Aug.  6, 2021. Six hundred seventy-nine were prescribed ivermectin or a placebo, and the remaining 2,157 received another intervention. 

Overall, 100 patients in the ivermectin group and 111 in the placebo group had a primary-outcome event, defined as either a hospital admission or a prolonged emergency department visit. Of the 211 primary-outcome events, 171 were hospital admissions. There were no significant effects of ivermectin on secondary outcomes or adverse events.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Patient Safety & Outcomes

Advertisement

Comments are closed.